The Mycobacterium bovis bacille Calmette-Guérin (BCG) has been widely used as a live bacterial vaccine against Mycobacterium tuberculosis infection. Its recombinant form, rBCG, which has been used successfully to express foreign antigens and to induce immune responses, has been proposed as a vaccine candidate against a number of diseases (26, 32, 33) , especially human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) (11, 13, 30) . Moreover, mucosal immunization of rBCG has been found to elicit a long-term virus-specific immunity in animals (10, 14, 15) , even in Th1-and Th2-deficient conditions (10) . In short, an rBCGbased vaccine offers several clear advantages over other types of recombinant vector-based approaches in that it (i) induces cellular immune responses that are maintained for at least 1 to 2 years; (ii) is easy to administer, usually requiring only one or two immunizations; (iii) and is affordable because it can be easily and cheaply produced. These findings suggest that rBCG could be a potent vaccine against HIV-1 infection, one that is likewise capable of inducing safe, virus-specific immunity. However, the results described above were obtained with high doses of rBCG, doses 10-to 100-fold larger than that needed for a practical BCG vaccination dose against tuberculosis in humans (7, 11) . Therefore, the low immunogenicity seen in rBCG-inoculated animals is likely due to their inoculation with only a "normal," not a high, vaccination dose (15) . Moreover, high doses of BCG administration in vivo may also act as the driving force for the replication of the immunodeficiency virus and its dissemination by hyperactivating T cells (6, 41) .
We sought here to produce an rBCG vaccine that would be efficacious even in the low doses required for human vaccination. Because low-dose immunization of rBCG has been suggested to act as a prophylactic vaccination against HIV-1 (15, 28), we adopted the preferred codon of BCG to enhance the expression of the foreign HIV gene. In recombinant protein production, the potency of codon-optimized gene expression systems was demonstrated in Escherichia coli (39) and in mammalian cells (42) . These results clearly show that codon-optimized recombinant genes induce vigorous expression by foreign genes in the host. Since 1998, many groups have reported that a sequence-modified DNA vaccine confers high immunogenicity against various foreign antigens, e.g., listeriolysin O of Listeria monocytogenes (37) , HIV-1 Gag (43), Env (3), tetanus toxin (34), L1 protein of human papillomavirus (18) , and merozoite surface protein 1 of Plasmodium falciparum (25) . Most of these studies focused on demonstrating how mammalian codon usage bias efficiently enhanced the expression and immunogenicity of foreign antigens in DNA vaccination. However, although the effect of codon optimization in mammalian cells has been well documented, its effect in recombinant BCG vector-based vaccines has never been fully elucidated.
RESULTS
Mycobacterial codon usage optimization of HIV-1 gag p24 gene and construction of an rBCG encoding the codon-optimized gene. In order to determine whether mycobacterial codon optimization could enhance the expression of the HIV gene in vitro, we first targeted the HIV-1 subtype B NL4-3 gag p24 gene for our research. Once we had designed the mycobacterial codon-optimized p24 gene, aligned it with the wildtype gene, and deduced the amino acid sequence (Fig. 1) , we determined that the total GϩC content of the coding region in the synthetic p24 gene was higher (67.4%) than that of the wild-type p24 gene from pNL4-3 (43.4%). (A translation table showing all 20 amino acids used in the present study is available [ Table S1 in the supplemental material]). These two genes were initially cloned into the pUC-hspK vector (Fig. 2a) and subcloned into the pSO246 vector (Fig. 2b ). Once these expression vectors were transformed into the BCG Tokyo172 strain, rBCG-p24Mu (with optimal codon usage of the p24 gene) and rBCG-p24Wt (with wild-type codon usage) were selected for further experimentation.
Effects of codon usage modification on the expression levels of HIV-1 Gag p24 in vitro. We next sought to compare the expression levels of the p24 gene in the two types of BCG-HIV recombinants by studying the kinetics of the growth curve of the cultured rBCG cells and by measuring the levels of p24 protein to assess the production ability of the HIV antigen (Fig. 3) . Using Western blot analysis at 2-week intervals, we observed that recombinant p24 protein in each of the lysates of rBCG-p24Wt and -p24Mu consistently appeared as a single band measuring ca. 24 kDa (lanes 1 and 2 of Fig. 3a , respectively). The p24 antigen expression level of rBCG-p24Mu was 37-fold higher (175.0 Ϯ 25.1 ng/5 ϫ 10 7 CFU of bacilli) than that of rBCG-p24Wt (4.7 Ϯ 0.3 ng/5 ϫ 10 7 CFU of bacilli) (Fig. 3b) . Both rBCG-p24Mu and -p24Wt showed a more normal BCG growth curve than did the rBCG-pSO246 control transformant, and both peaked 21 days after cell culture (Fig.  3c) , suggesting a correlation between p24 antigen generation and the growth rate of cultured rBCG-p24Mu. Thus, the codonoptimized BCG recombinant was successfully generated and found to express remarkable levels of p24 antigen, i.e., almost 200 ng of p24 antigen/5 ϫ 10 7 CFU or 1 mg of bacilli. Codon optimization of the HIV-1 Gag p24 antigen in rBCG generates strong HIV-specific immune responses in mice after intradermal immunization. We then analyzed how the modification of codon usage affected the immunogenicity of BCG vector-based vaccines encoding the HIV-1 gag p24 antigen gene. 35 BALB/c mice were divided into three experimental groups of 10 mice each, with the remaining five mice administered saline alone and used as normal healthy controls. Five mice from each experimental group were intradermally immunized with 0.01 mg, and five mice from each group were immunized with 0.1 mg of rBCG-p24Mu, -p24Wt, and -pSO246. responses between rBCG-p24Mu and -p24Wt were statistically significant comparing pool 2 (P ϭ 0.010) and pool 1-5 (P ϭ 0.001). No p24-specific proliferation was detected in either rBCG-pSO246-immunized mice or normal healthy controls (data not shown). PPD-specific lymphocyte proliferations were obtained in all immunized animals similarly (stimulation indices were ca. 7).
In addition, p24-specific IFN-␥-secreting cells were determined by ELISPOT assay. Both pooled p24 peptides (pool 1-5) and rp24-specific SFCs were detected in mice immunized with 0.1 mg of rBCG-p24Mu and -p24Wt but not in those immunized with the same dosage of rBCG-pSO246 (Fig. 5) . In rBCG- 6 splenocytes, respectively). These differences in response by groups immunized with rBCG-p24Mu and -p24Wt to peptides and to rp24 were also statistically significant (peptides, P ϭ 0.033; rp24, P ϭ 0.031). PPD-specific SFCs were strongly expressed in all mice receiving rBCGs (670 Ϯ 180 SFC/10 6 splenocytes). Furthermore, similar levels of rp24-specific IFN-␥ SFC activity were observed in splenocytes of rBCGp24Mu-immunized animals even 6 months p.i. (402 Ϯ 198 SFC/10 6 splenocytes, data not shown). Furthermore, we studied whether these IFN-␥ ELISPOT activities were attributed to major histocompatibility complex class I-restricted CD8
ϩ -T-cell response with 12 BALB/c mice immunized with 0.1 mg of rBCG-p24Mu (n ϭ 4), -p24Wt (n ϭ 4), or -pSO246 (n ϭ 4). After 2 weeks p.i., the mice were sacrificed, and their spleens were used for the study. By peptide-antigen-specific IFN-␥ ELISPOT assay, H-2 d -restricted CD8
ϩ -T-cell responses specific for the CD8 ϩ -T-cell epitope A9I were detected in the two animal groups immunized with rBCG-p24Mu and -p24Wt (Fig. 6b) . In rBCG-p24Mu-immunized mice, stimulation with 50 M A9I resulted in 130 Ϯ 16 SFC/10 6 splenocytes, activities significantly higher than that obtained by immunization with rBCG-p24Wt (70 Ϯ 21 SFC/ 10 6 splenocytes, P ϭ 0.011). Furthermore, by using magnetic cell sorting, the CD8 ϩ -T-cell-depleted cell fractions were purified to be Ͼ97% and Ͼ99% viable (Fig. 6a) . The CD8 ϩ -Tcell response of immunized animal groups decreased significantly upon stimulation with A9I peptide compared to nonseparated splenocytes (rBCG-p24Mu immunized, 15 Ϯ 12 SFC/10 6 cells, P ϭ 0.001; rBCG-p24Wt immunized, 3 Ϯ 3 SFC/10 6 cells, P ϭ 0.006) ("CD8-depleted" in Fig. 6b ). No A9I-specific IFN-␥ responses were detected in rBCG-pSO246-immunized mice either whole or CD8-depleted splenocytes were used (data not shown).
Finally, sera from all animals immunized with 0.1 mg of rBCG-p24Mu, -p24Wt, and -pSO246 were assessed for specific antibody generation at 10 weeks p.i. by endpoint antibody-ELISA against rp24 and PPD (Fig. 7) . Again, only low levels of antibodies against rp24 were generally elicited in animals immunized with rBCG-p24Mu and -p24Wt (antibody titers in sera of 10 2.41 and 10 2.03 , respectively). Moreover, PPD-specific antibodies were similarly detected in all immunized animals at titers of ca. 10 3 . In summary, virus-specific cell-mediated immunity was significantly induced during the initial immune response, but its antibody response was low.
DISCUSSION
In this study, we have clearly demonstrated that codon optimization is a useful strategy for enhancing foreign antigen expression in rBCG and for obtaining significant levels of foreign antigen-specific immune responses. This strategy is key to rBCG-HIV vaccine development, since low-dose immunization and/or intradermal immunization with 0.1 mg of codonoptimized rBCG has proven effective for induction of HIVspecific cellular immunity by (i) allowing for a smaller dosage of rBCG, one that is far more practicable for use in human tuberculosis vaccination than the 1 to 10-mg dose otherwise ϩ -T-cell responses by peptide-specific IFN-␥ ELISPOT assay. Effect of CD8
ϩ -T-cell depletion from splenocytes from immunized animals was studied by measuring the A9I peptide-specific IFN-␥ ELISPOT response of whole or CD8-depleted splenocytes. Solid and open columns indicate the numbers of SFCs of rBCG-p24Mu and -p24Wt-immunized mice, respectively. The data represent the mean numbers of SFCs/10 6 cells plus one standard deviation. The asterisk indicates statistical significance (P Ͻ 0.02 against rBCG-p24Wt-immunized mice). required, and by (ii) thereby reducing the risks associated with high-dosage cutaneous administration, including adverse local skin reactions, possible association with Th2-type immune responses, or exacerbation of retroviral infections. Given these results, rBCG is clearly poised to play a key role in the development of an HIV/AIDS vaccine.
When the mycobacterial codon usage of the p24 antigen gene of the HIV-1 gag was optimized, the codon-optimized rBCG expressed nearly 40-fold more antigen than did the wild-type rBCG. This enhancement of the Gag p24 expression level in rBCG is on a par with the 10-to 50-fold increase seen when DNA vaccine is codon optimized (3) . Why was the mycobacterial codon optimization so effective? BCG is a high GϩC gram-positive bacteria, with a genomic GϩC content ca. 64.8%, and so has a strong bias toward C-and G-ending codons for every amino acid. Overall, the GϩC content at the third position of codons is 81.0% (2) . From the accumulated information on BCG genes (24) , it should be noted that the AGA codon for Arg and the TTA codon for Leu make up only 0.9 and 1.6% of the total codons for Arg and Leu, respectively. In contrast, HIV-1 prefers the adenine or the thymidine at the third position of the codon (60.9%). In the coding sequence of the p24 gene of HIV-1 gag, 9 out of 11 Arg codons used AGA and 6 out of 18 Leu codons used TTA. Because it is generally accepted that codon preference correlates with the amount of aminoacyl tRNA in unicellular organisms (12) , only low levels of aminoacyl tRNA for AGA and TTA codons would be expected in the BCG cell. These low levels of aminoacyl tRNA for AGA and TTA codons might help explain why the codonoptimized p24 gene was highly expressed in BCG.
Recombinant HIV-1 Gag p24 antigen expression in codonoptimized rBCG is 175 ng/mg of bacilli of BCG Tokyo172 or ca. 5.3% of the total cytoplasmic rBCG protein, when calculated using the method of Langermann et al. (17) . The previously reported production levels of recombinant HIV protein were all for non-codon-optimized BCG using a different expression system and a different BCG strain. The levels varied from 1% of cellular protein (HIV-1 Nef [40] and SIV mac251 Gag [22] ) to 0.1% of the HIV-1 Gag protein (1), suggesting that codonoptimized recombinant HIV-1 protein induced responses 5-to 50-fold higher than those previously reported for non-codonoptimized rBCG. The codon-optimization of HIV Gag p24 is also effective in elicitation of antigen-specific CD8 ϩ -T-cell responses in animals. Since there is no difference in the growth/ persistence in the various BCG (S. Yamamoto et al., unpublished data), the enhanced expression of the HIV protein by the recombinant construct suggests that it is responsible for the enhanced immunogenicity of the codon-optimized rBCG vaccine.
A successful preventive HIV vaccine must not only effectively protects against HIV-1 or SIV, a goal already achieved in nonhuman primate AIDS models using different vaccine modalities, but also will prove safe for use in humans. Instead of seeking to elicit sterilizing protection from the HIV infection, current vaccine research on HIV/AIDS is focused mainly on the induction of efficient cellular immune responses that may play a critical role in protective immunity.
One of the prospective measures is to evoke host immunity by delivering recombinant vector-based vaccines expressing recombinant antigens, e.g., modified vaccinia virus Ankara (4, 21) , adenovirus type 5 (29) , fowlpox virus (16), canarypox virus (8) , and NYVAC (5). In combination with boosting or priming antigens, most of these recombinant vector-based vaccines effectively induce antiviral immunity. We also showed that rBCG could induce long-lasting anti-HIV-1 or -SIV specific immunity in small animals (14) . In the present study, we have demonstrated the promise of a codon-optimized rBCG-HIV vaccine, one which could, even at low doses, elicit long-lasting cell-mediated immune responses without triggering humoral immunity.
Previous reports have demonstrated that a high-dose intravenous inoculation of BCG can induce disease progression, as it did, for example, with BCG-specific CD4
ϩ -T-cell activation in monkeys infected with SIV (6) . Others have reported a correlation between the magnitude of T-cell activation of CDR3-restricted cells and the disease progression to AIDS in monkeys (41) . These results suggest that these CD4 ϩ T cells, once activated by a high dose of any live vaccine, may become infectious and even lead to the replication of the immunodeficiency virus at the coinfection stage. In this regard, our previous study indicated that high doses of BCG did indeed induce a remarkable expansion of I a -positive activated T cells in guinea pigs but that intradermal inoculation with 0.1 mg of BCG, the common dose and route of BCG vaccination in humans, did not (35) .
In showing that a low-dose vaccination with rBCG-HIV is both possible and practicable with the mycobacterial codon optimization of the foreign HIV gene, we offer here a way around this problem. Collectively, these results suggest that a novel vaccination strategy using a low dose of codon-optimized rBCG-HIV, one comparable to the common dosage used for BCG vaccination in humans, might promote stable cell-mediated immune responses and thereby help establish positive immunity against subsequent immunodeficiency virus infection. 
